empty
 
 
de
Suche
Support
Sofortige Kontoeröffnung
Handelsplattform
Einzahlen / Auszahlen
Suche
Für Anfänger Für Trader Für Partner Machen Sie eine Pause Über uns
de
#BMY Zurück zur Liste #CGC

Währungsrechner

BioNTech SE
83.75 USD
10 Mar 2026 22:59
Preisveränderung (% chg)
$0
(0%)
Schließung
Schließung

Schließungspreis, der vorherige Tag.
$101.28
Eröffnung
Eröffnung

Eröffnungspreis.
$98.55
Höchstpreis
Höchstpreis

Höchstpreis für den letzten Tag des Handels.
$101.28
Mindestpreis
Mindestpreis

Mindestpreis
$79.1
52 Wochen. max.
52 Wochen. max.

Höchstpreis für die letzten 52 Wochen.
$109.17
52 Wochen. min.
52 Wochen. min.

Mindestpreis für die letzten 52 Wochen.
$79.1
Archiv herunterladen
Buy
83.75
Sell
83.75
Open the chart in full screen view
Buy
83.75
Sell
83.75
Archiv herunterladen
Open the chart in full screen view

BioNTech SE. About company

BioNTech SE. is a biotechnology company founded in 2008 in Germany. It develops medicines for the treatment of cancer, HIV, tuberculosis, and other diseases.

In 2020, BioNTech SE. participated in the creation of a COVID-19 vaccine together with Pfizer and Fosun Pharma. As of March 2022, BioNTech SE. and Pfizer have delivered more than 3.1 billion doses of vaccines.

The company owns a factory in Marburg but most of the vaccines are produced at Pfizer and other companies' factories. In 2021, BioNTech SE. announced its plan to open its first vaccine manufacturing facility in Rwanda.

Its market cap currently stands at $33.38 billion. In 2021, its revenue amounted to $18,976 billion. The net profit totaled $10,292 billion.

BioNTech SE. shares and what factors impact them

BioNTech SE. stock has been traded on the NASDAQ exchange under the BNTX ticker since 2019. The initial price was $15.

Nowadays, the stock price is estimated at $135-$138. Over the year, it fluctuated in the range of $117 - $370.

In 2022, the company paid dividends to the shareholders in the amount of $2.11 per share. The yield was 1.65%.

You should pay attention to the following factors when trading its stock:

  • News about rivals that produce medicines and vaccines;
  • Likelihood of a high profit from the development of an Omicron vaccine;
  • Dependence on government agencies that regulate the industry and the production of coronavirus vaccines.

Können Sie momentan nicht telefonieren?
Dann stellen Sie Ihre Frage im Chat.